Content
01/28/2025
Valencia Spain
Quibim
completed $50 million Series A Round funding. Investors include
Buenavista Equity Partners (lead), Asabys Partners (lead), UI Investissement, GoHub Ventures, Amadeus Capital Partners, APEX Ventures, Partech International, Adara Ventures, Kfund.
About
Quibim is a healthtech company pioneering tools that unlock imaging data to improve patient outcomes. Quibim is at the forefront of imaging biomarkers research in life sciences, driving the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 170 healthcare institutions, research centers, hospitals, and clinical facilities are using Quibim products globally. In addition, Quibim has partnerships with Merck KGaA to develop imaging biomarker models to predict responses of cancer patients to immunotherapy and inform decisions in its global drug development efforts and with Phillips to launch AI-based imaging and reporting solutions for MRI prostate exams. Quibim has offices in New York City, US, Cambridge, UK, Valencia, Madrid, and Barcelona, Spain.
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
